Abstract
A striking feature of the provision of renal replacement therapy (RRT) for end-stage renal failure is the wide variation in the proportion of patients receiving peritoneal dialysis (PD) compared with haemodialysis (HD). It is likely that in many situations, this represents underutilization of PD. This means that some patients are missing the option of receiving PD with its associated benefits as part of an integrated approach to RRT. There are also important economic implications of underuse of PD. The management of end-stage renal failure poses a significant challenge to healthcare budgets, with PD in most settings having a significantly lower cost therapy than in-centre HD.

This publication has 31 references indexed in Scilit: